Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
128 Results for "
cell cycle progression
" in MedChemExpress (MCE) Product Catalog:
Products (128)
128 Results for "cell cycle progression" in MCE Product Catalog:
Cat. No.: HY-181624
Research Areas:
BTK ligand-19 is a PROTAC ligand of BTK, which is used to synthesize the PROTAC-based BTK degrader PROTAC BTK degrader-14 (HY-181623). BTK ligand-19 regulates cell apoptosis, cell cycle progression and kinase signaling cascades. BTK ligand-19 is applied in cancer research .
Cat. No.: HY-L148
72 compounds
The TCA cycle (tricarboxylic acid cycle)—is also known as the Krebs cycle or the citric acid cycle (CAC). The TCA cycle is a series of chemical reactions that release stored energy through the oxidation of acetyl-CoA in carbohydrates, fats, and proteins.
For decades, the TCA cycle has been considered as the central pathway for cell oxidative phosphorylation to produce energy and biosynthesis. Research shows that TCA cycle is associated with many diseases, especially cancer. In colon carcinoma, liver cancer and other cancers, there are mutations that lead to the imbalance of TCA cycle metabolites, indicating that TCA cycle may be related to the occurrence of cancer. Understanding the role and molecular mechanism of TCA cycle in inhibiting or promoting cancer progression will promote the development of new metabolite-based cancer treatment methods in the future.
MCE supplies a unique collection of 72 compounds related to the TCA cycle. MCE TCA Cycle Compound Library is a useful tool for the TCA cycle related research and anti-cancer drug development.
Cat. No.: HY-L004
3,522 compounds
DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair.
MCE owns a unique collection of 3,522 cell cycle/DNA damage-related compounds which can be used in the research of the same.
Cat. No.: HY-182463
CAS No.: 173792-68-2
Target:
Research Areas:
Moreollic acid is a PTP1B inhibitor, with an IC50 of 4.44 μM and a Ki of 1.75 μM against human targets. Moreollic acid blocks cell cycle progression from the G1 to S phase and inhibits tumor cell proliferation. Moreollic acid can be used in research related to type 2 diabetes, obesity, colon cancer and other cancers .
Cat. No.: HY-L231
25 compounds
The TCA cycle (tricarboxylic acid cycle)—is also known as the Krebs cycle or the citric acid cycle (CAC). The TCA cycle is a series of chemical reactions that release stored energy through the oxidation of acetyl-CoA in carbohydrates, fats, and proteins.
For decades, the TCA cycle has been considered as the central pathway for cell oxidative phosphorylation to produce energy and biosynthesis. Research shows that TCA cycle is associated with many diseases, especially cancer. In colon carcinoma, liver cancer and other cancers, there are mutations that lead to the imbalance of TCA cycle metabolites, indicating that TCA cycle may be related to the occurrence of cancer. Understanding the role and molecular mechanism of TCA cycle in inhibiting or promoting cancer progression will promote the development of new metabolite-based cancer treatment methods in the future.
MCE supplies a unique collection of 25 key intermediates of the TCA cycle, which can be utilized for TCA-related research and metabolomics identification studies.
Cat. No.: HY-126778
CAS No.: 15228-71-4
Synonyms: Leurosidine
Target:
Cat. No.: HY-180192
CAS No.: 3106089-54-4
Dehydroxy-oridonin-vinyl ester (Compound 6k) is an anti-cancer agent. Dehydroxy-oridonin-vinyl ester exhibits extremely strong anti-proliferative activity against SU-DHL-6 cells, with its IC₅₀ value being 0.12 μM. Dehydroxy-oridonin-vinyl ester induces cell apoptosis by inhibiting the activation of the PI3K/Akt signaling pathway, without affecting the cell cycle progression. Dehydroxy-oridonin-vinyl can be used for the study of lymphoma .
Cat. No.: HY-189359
CAS No.: 872984-72-0
Apoptosis inducer 63 is an Apoptosis inducer. Apoptosis inducer 63 induces apoptosis and interferes with cell cycle progression through G2/M phase arrest and subsequent G1 phase accumulation. Apoptosis inducer 63 exhibits anticancer activity against colorectal cancer, lung cancer, and epithelioid carcinoma. Apoptosis inducer 63 can be used for research on colorectal cancer .
Cat. No.: HY-100789R
CAS No.: 1312471-39-8
Research Areas:
ON1231320 (Standard) is the analytical standard of ON1231320 (HY-100789). This product is intended for research and analytical applications. ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC50 of 0.31 μM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity .
Cat. No.: HY-184830
CAS No.: 77182-66-2
Target:
Cat. No.: HY-L025
11,237 compounds
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc.
MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.
Cat. No.: HY-118900
CAS No.: 639087-64-2
CP-654577 is a selective ErbB2 inhibitor with an IC50 of 11 nM. CP-654577 downregulates the Notch1 signaling pathway. CP-654577 upregulates p27 kip1, reduces the levels of Cyclins D and E, and inhibits G1 phase progression of the cell cycle. CP-654577 induces cell Apoptosis, downregulates activated Akt, and suppresses tumor growth in athymic mice. CP-654577 can be used in breast cancer-related research .
Cat. No.: HY-P3303
CAS No.: 146556-41-4
PF1070A is a Pf HDAC1 inhibitor with an IC50 of 0.0011 μM. By inhibiting histone deacetylase (HDAC) activity, PF1070A induces histone H4 hyperacetylation and chromatin remodeling, arrests cell cycle progression prior to nuclear division, and exhibits antimalarial activity against multidrug-resistant Plasmodium falciparum strains with high selectivity. PF1070A is suitable for use in malaria research .
Cat. No.: HY-28086
CAS No.: 116452-88-1
Target:
Research Areas:
CDC25-IN-2 (Compound 1d) is a selective phosphatase Cdc25 inhibitor with IC50 values of 44.4, 55.2 and 53.9 μM for human Cdc25A, Cdc25B, Cdc25C. CDC25-IN-2 can block the cell cycle progression by inhibiting the activity of Cdc25 phosphatase. CDC25-IN-2 can be used for the research of cancer .
Cat. No.: HY-119709
CAS No.: 1353384-61-8
AQ-101 is a MDM2 degrader. Upon binding to MDM2, it blocks the MDM2-MDM4 interaction, inducing autoubiquitination and proteasome-mediated degradation of MDM2. AQ-101 activates p53, upregulates downstream targets including p21 and PUMA, and induces apoptosis and cell cycle arrest in tumor cells. AQ-101 inhibits the progression of acute lymphoblastic leukemia in xenograft animal models. AQ-101 can be used for research related to acute lymphoblastic leukemia .
Cat. No.: HY-P11908
Research Areas:
Cat. No.: HY-189200
CAS No.: 3006101-94-3
Target:
Research Areas:
AZ'4331 is an orally active pan-TEAD family inhibitor, with an IC50 of 0.381 μM against TEAD1, 0.020 μM against TEAD2, 0.014 μM against TEAD3, and 0.031 μM against TEAD4. AZ'4331 slows cell cycle progression. AZ'4331 exerts effects in cancer xenograft models with dysregulated Hippo pathway. AZ'4331 can be used to study cancers with altered Hippo pathways, including mesothelioma, head and neck squamous cell carcinoma, and EGFR-mutant non-small cell lung cancer .
Cat. No.: HY-L201
3,628 compounds
Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others.
MCE collects 3,628 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.
Cat. No.: HY-184649
CAS No.: 2922859-30-9
CDK2-IN-60 is an orally active, ATP-competitive selective CDK2 inhibitor with a Ki of 77 pM. CDK2-IN-60 has high selectivity for both CDK4 and CDK1. CDK2-IN-60 blocks G1/S cell cycle progression to suppress proliferation of CCNE1-amplified tumor cells. CDK2-IN-60 serves as a lead chemical probe for investigating CCNE1-amplified cancers and CDK4/6 inhibitor-resistant HR-positive breast cancer .
Cat. No.: HY-182331
CAS No.: 3059574-58-9
WCF-598 is a RXRγ (Kd: 234.2 nM) PROTAC degrader. WCF-598 induces RXRγ degradation via the ubiquitin-proteasome pathway and binds directly to RXRγ. WCF-598 indirectly induces AR-V7 degradation, impairs the stability of the RXRγ-AR-V7 complex, downregulates AR-V7 levels, and inhibits the transcription of downstream target genes of AR-V7. WCF-598 induces tumor cell apoptosis, inhibits cell proliferation, activates the p53 signaling pathway, and suppresses cell cycle progression. WCF-598 can be used for the research of prostate cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
